BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Sequella, Inc. 

9610 Medical Center Drive, Suite 200

Rockville  Maryland  20850  U.S.A.
Phone: 301-762-7776 Fax: 301-762-7778


SEARCH JOBS


Industry
Biotechnology






 Company News
Vaccine-Fixated Pfizer Inc. (PFE) Licenses Out TB Drug to Sequella, Inc. 7/17/2013 6:51:41 AM    More...
Biotech Venture Fund's Portfolio Company, Infectex, Enrolls First Multi-Drug Resistant (MDR-TB) Patients in Pivotal Clinical Trial of SQ109, Licensed From Sequella, Inc. 12/19/2012 9:50:54 AM    More...
Maxwell Biotech Venture Fund's Portfolio Company, Infectex, Receives Russian Regulator's Approval to Conduct Pivotal Clinical Trial for Sequella, Inc.'s Antibiotic, SQ109, for Tuberculosis 7/26/2012 9:54:00 AM    More...
Sequella, Inc. Licenses Rights to Commercialize SQ109 for Tuberculosis in Russia to Maxwell Biotech Venture Fund Subsidiary; Deal Valued at Over $100 Million to the Parties 4/25/2011 9:52:49 AM    More...
Sequella, Inc. Awarded $4.6 Million in New National Institutes of Health (NIH) Grants to Expand Anti-Infectives Pipeline 4/4/2011 9:14:18 AM    More...
John H. Friedman of Easton Capital Investment Group Joins Sequella, Inc. Board of Directors 1/31/2011 9:13:30 AM    More...
Sequella, Inc. Files IND and Receives FDA Go-ahead for Phase 2 Trial of SQ109 in Helicobacter pylori-associated Duodenal Ulcers 12/6/2010 11:33:29 AM    More...
Sequella, Inc. Receives International Support for Phase 2 Clinical Trials of SQ109, its Lead Antitubercular Drug Candidate 10/18/2010 12:00:32 PM    More...
Sequella, Inc.: Two New Tuberculosis (TB) Drugs Show Significant Synergy In Vitro 7/26/2010 11:11:26 AM    More...
Sequella, Inc. and National Institutes of Health (NIH) Sign Exclusive Worldwide Licensing Agreement for SQ109 for New Infectious Disease Indications 11/17/2009 9:58:39 AM    More...
123

//-->